Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

0
Xylem (XYL) Battles Cost Pressure on Solid Growth Drivers

2018-07-09 zacks
On Jul 9, we issued an updated research report on premium diversified machinery company, Xylem Inc. (XYL - Free Report) . The company currently carries a Zacks Rank #3 (Hold). Over the past 60 days, the Zacks Consensus Estimate for the stock’s earnings remained unchanged for both 2018 and 2019 at $2.89 and $3.37, respectively, reflecting neutral brokers’ sentiments. Let’s dig into the fundamental aspects influencing the performance of this stock.
ROP POOL GGG PUR XYL GTLS

0
DIRTT Announces New Chief Financial Officer

2018-05-28 globenewswire
CALGARY, Alberta, May 28, 2018 (GLOBE NEWSWIRE) -- DIRTT Environmental Solutions Ltd. (“DIRTT” or the “Company”) (TSX:DRT), an interior construction company using technology for client-driven design and manufacturing, today announced the appointment of Geoffrey D. Krause, CA, CPA, as its chief financial officer, effective June 4, 2018.
PUR DRTTF XYL DRT

0
Xylem (XYL) Q1 2018 Results - Earnings Call Transcript

2018-05-01 seekingalpha
Welcome to the Xylem First Quarter 2018 Earnings Conference Call. At this time, all participants have been placed on a listen-only mode and the floor will be open for your questions following the presentation.
PUR XYL

56
Xylem (XYL) to Report Q1 Earnings: What's in the Cards?

2018-04-27 zacks
Xylem Inc. (XYL - Free Report) is slated to report first-quarter 2018 results before the opening bell on May 1. In the last four quarters, the company reported better-than-expected results in two quarters, while lagged estimates in one and met in the other. The average four-quarter earnings surprise is a negative 0.02%. In the last reported quarter, its earnings of 76 cents came in line with the Zacks Consensus Estimate.
CATR PUR CAT XYL SAH ALRM

4
DIRTT and Iron Compass agree on board refreshment

2018-04-16 globenewswire
CALGARY, Alberta, April 16, 2018 (GLOBE NEWSWIRE) -- DIRTT Environmental Solutions Ltd. (“DIRTT” or the “Company”) (TSX:DRT), an interior construction company using technology for client-driven design and manufacturing, announces it has agreed with recommendations provided by Iron Compass, LLC to add John (Jack) Elliott and Ronald Kaplan to the board of directors of the Company (the “Board”), effective immediately.
HSC PUR TREX DRTTF DRT

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to TSX:PUR / Pure Technologies Ltd on message board site Silicon Investor.

Coherus BioSciences: Pure Play In The Emerging Biosimilar In CFA Vs. Columbia Business School Vs. Pure Self-education
CFA Vs. Columbia Business School Vs. Pure Self-education Intu0027l Pursuit (T.IPJ)
HAWKEYE GOLD PURCHASE TOP PROPERTY - YUKON ADOT - BIOMODA: Profitable Technology with Purpose
Do handguns serve a purpose other than killing people? SPUR VENTURES STARTING TO MOVE TARGET 9.00
Biopure Corp (BPUR) Trivial Pursuit